1 Article

- 2 Pediatric Multi-Organ Dysfunction Syndrome: Analysis by an
- 3 Untargeted "Shotgun" Lipidomic Approach Reveals Low-abundance
- 4 Plasma Phospholipids and Dynamic Recovery Over 8-Day Period, a
- 5 Single-Center Observational Study
- 6 Mara L. Leimanis Laurens^{1,2}, Karen Ferguson¹, Emily Wolfrum³, Brian Boville^{1,2}, Dominic
- 7 Sanfilippo^{1,2}, Todd A. Lydic⁴, Jeremy W. Prokop^{2,5}, Surender Rajasekaran^{1,2}
- Pediatric Critical Care Unit, Helen DeVos Children's Hospital, 100 Michigan Street NE, Grand Rapids, MI,
 United States
- ²Department of Pediatric and Human Development, College of Human Medicine, Michigan State University,
 Life Sciences Bldg. 1355 Bogue Street, East Lansing MI 48824, United States
- ³Van Andel Institute, Bioinformatics & Biostatistics Core, 333 Bostwick Avenue NE, Grand Rapids, MI, United
 States
- ⁴Department of Physiology, Collaborative Mass Spectrometry Core, 567 Wilson Road, East Lansing, MI, 48824,
 United States
- ⁵Department of Pharmacology and Toxicology, Michigan State University, 1355 Bogue Street, East Lansing,
 MI, 48824, United States
- 18 *Correspondence: mara.leimanis@spectrumhealth.org

19 Abstract: Lipids are stable molecules involved in metabolism and inflammation. We investigated 20 the plasma lipidome for markers of severity and nutritional status in critically ill children. Children 21 with multi-organ dysfunction syndrome (MODS) (n=24) were analyzed at three time points and 22 cross referenced to sedation controls (n = 4) for a total of N=28. Eight of the patients with MODS, 23 needed veno-arterial extracorporeal membrane oxygenation (VA ECMO) support to survive. Blood 24 plasma lipid profiles were quantified by nano-electrospray (nESI), direct infusion high 25 resolution/accurate mass spectrometry (MS), and tandem mass spectrometry (MS/MS) and 26 compared to nutritional profiles and PEdiatric Logistic Organ Dysfunction (PELOD) scores. 27 PELOD scores were not significantly different between MODS and ECMO cases across time-points 28 (p = 0.66). Lipid profiling provided stratification between sedation controls and all MODS patients 29 for lysophosphatidylserine (lysoPS) (p-value = 0.004), total phosphatidylserine (PS) (p-value = 30 0.015), and total ether-linked phosphatidylethanolamine (PE) (p-value = 0.03). Phospholipids in 31 patients needing ECMO were observably closer to sedation controls than other MODS patients. 32 Nutrition intake revealed changes in lipid profiles that corresponded to calorie and protein intake. 33 Lipid measurement in the intensive care environment shows dynamic changes over an 8-day PICU 34 course, suggesting novel indicators for defining critically ill children.

Keywords: lipidomics, pediatrics, critical illness, multi-organ dysfunction syndrome,
 phospholipids, nutritional intake

37 1. Introduction

38 It has been estimated that twenty percent of critically ill patients present to the pediatric 39 intensive care unit (PICU) with multi-organ dysfunction syndrome (MODS) [1]. This group 40 experiences ten times the mortality rate compared to other PICU patients [2]. In this group, there 41 exists a smaller cohort of patients that require aggressive life support measures such as 42 extracorporeal membrane oxygenation (ECMO) with up to 45% reported mortality [3]. The reasons 43 for this are unclear. Understanding MODS has become increasingly important as COVID-19 patients 44 that present with MODS experience a more protracted ICU course and suffer higher mortality than 45 those have single system involvement [4,5].

46 Critically ill children experience a hypermetabolic stress response and catabolic state [6]. 47 During this acute illness phase a rapid breakdown of adipose tissue occurs leading to multiple

It is made available under a CC-BY-NC-ND 4.0 International license .

48 sequelae including chronic inflammation, hyperglycemia, and further damage to organ function by 49 fatty infiltration [7,8]. These patients have often ceased oral intake thus being deprived of optimal 50 nutritional support [9,10]. Critical illness by itself is characterized by mitochondrial dysfunction [11] 51 and perturbations in β -oxidation [12] from organ failure. MODS results from a variety of triggers 52 both infectious and non-infectious that results in a common phenotype of organ dysfunction. How 53 lipid levels and composition vary over time and between patients with MODS alone vs. those 54 progressing to circulatory collapse and the need for ECMO remains unknown. This knowledge 55 could enable optimization of nutrition therapy as well as identify new targets for supporting organ 56 function in the face of critical illness.

57 Unlike some biological molecules, lipids are stable and abundant, making them attractive 58 metabolites to study in MODS patients admitted in the PICU. The role of lipids in critical illness and 59 acute inflammation has been explored in adults [13] and children [14], and lipids are crucial for 60 membrane formation, signaling, and metabolism [15-19]. It is well known that disruption of lipid 61 signaling pathways and metabolism leads to inflammatory disorders [20]. This can be amplified 62 when exogenous lipid sources from diet are altered, such as in acute illness leading to malnutrition 63 and poor outcomes [21]. Specifically, phospholipids are known to play a role in a wide array of 64 diseases (see review [22]). Thus, lipids likely serve as markers for tissue injury, inflammation, 65 metabolic dysfunction, and indicators of nutritional status.

66 A two time-point lipidomics study focusing on single organ injury in adult patients with acute 67 respiratory distress syndrome (ARDS) revealed 90 significantly different lipids that distinguished 68 survivors from non-survivors [13]. We hypothesize that certain lipid classes can be used to 69 distinguish patients with MODS that need ECMO from those that recover with just medical 70 management accounting for both severity and nutritional status. Advances in the availability and 71 ease of use of lipid profiling in a clinical setting allows for signatures of highly personalized 72 lipidome profile to be developed to identify patients experiencing a severity of illness needing 73 ECMO [23], and such a strategy has potential to be more robust than the rise or fall of a single 74 biomarker. This study uses an unbiased untargeted lipidomics approach to enable a comprehensive 75 study of pediatric lipid profiles, determining the molecular compositions of analytes in blood 76 plasma using direct infusion high resolution/accurate mass spectrometry (MS) and tandem mass 77 spectrometry (MS/MS).

78 2. Materials and Methods

79 Study Population, Site and Sample Collection

Patients who were critically ill with MODS were recruited from the PICU at Helen DeVos Children's Hospital (HDVCH), a quaternary care facility in Western Michigan, after screening for eligibility and subsequently consented. The HDVCH PICU with over 1,500 admissions per year, and over 6,000 patient days, covers a 24-bed unit. Samples were collected at up to three independent time-points: baseline, > 48 hrs, and > 7 days, as long as they remained patients of the PICU. If a patient was discharged or passed away, no further samples were collected. All patients were consented prior to study recruitment as per local IRB approval (2016-062-SH/HDVCH) [24].

87 Patients were referred by the attending physician on service once MODS was recognized, 88 according to the following inclusion criteria: < 18 years of age; on vasopressors with a central line 89 and requiring invasive mechanical ventilation for respiratory failure as per criteria established by 90 Proulx et al. [25]. Patients presenting for routine sedation were used as controls. Patients were 91 excluded if they had a diagnosed auto-immune disease, were considering non-interventional 92 treatment options, had undergone cardiopulmonary bypass prior to onset of MODS, received 93 plasmapheresis prior to ECMO initiation, or were patients of the neonatal intensive care unit at the 94 time of consent. Blood samples were drawn in EDTA treated tubes, centrifuged, plasma was 95 separated, and stored at -80°C. In the case of ECMO patients, samples were drawn right before going 96 on the circuit with a median 3 days into their PICU admission (Figure 1-Study Flow Chart).

97

It is made available under a CC-BY-NC-ND 4.0 International license .

3 of 14

98 Figure 1: Flow diagram of the patient in the study (N=28)99



100

101 Data Collection

102 Basic demographic variables were extracted from the local electronic medical record (EMR). 103 Dietary history, and mode of feeding [nil per os (NPO), per os (PO), tube feeding (TF) +/- lipids, total 104 parenteral nutrition (TPN) +/- lipids] was extracted from the dietician's notes in the EMR. Percent 105 calories and protein were calculated from the resting energy expenditure [26] and daily required 106 intake [27], and qualified according to less than or equal to 33% of needs met, 34-66%, and greater or 107 equal to 67% nutritional needs met. Mode of respiratory support was qualified according to 108 mechanical ventilation (MV), nasal canula (NC), or room air (RA). All study data was collected and 109 managed using REDCap [28]. Severity of illness scores were retrieved through the Virtual Pediatric 110 Intensive Care Unit Performance Systems (VPS, LLC, Los Angeles, CA). PELOD was included given 111 that it is a measure of the first 10 days in the ICU. Median time to consenting patients was 2 days 112 from ICU admission, and Pediatric Index of Mortality 2 (PIM2) and Pediatric Risk of Mortality III 113 (PRISMIII) were both calculated during the first hours of ICU admission only, therefore not included 114 in our study analysis.

115 Blood Plasma Lipidomics Method

116 Blood samples collected in EDTA-treated tubes were immediately placed on ice and then spun 117 at 4°C (once for 15 minutes at 1500rpm; a second spin for 10 minutes at 10,000rpm), plasma was 118 harvested and frozen to -20°C, and -80°C for long-term. Lipidome profiles were determined from 119 thawed plasma, subjected to lipid extraction with acetone, methanol, and acetonitrile [29], followed 120 by analysis by nano-electrospray direct infusion high resolution/accurate mass spectrometry and 121 tandem mass spectrometry utilizing an LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific, 122 Waltham, MA) with the FT analyzer operating at 100,000 resolving power over two minutes. An 123 Advion Nanomate Triversa (Advion Biosciences, Ithaca, NY) served as the nano-electrospray source 124 with high-throughput autosampler. To verify lipid identities, Higher-Energy Collisional 125 Dissociation was utilized (at 100,000 resolving power). Lipidome analysis provided untargeted 126 assessment across all classes of glycerolipids (GC) (including mono-, di- and triglycerides), 127 phospholipids (PS), lyso-phospholipids (lysoPL), sphingolipids (SP), sterols, non-esterified fatty 128 acids (NEFA's) and fatty acids (FAs). Additional species analysis was completed on phospholipids, 129 triacylglycerides (TGs), diacylglycerides (DGs), cholesterol (chol), and sphingomyelins (SMs). Global 130 lipidome analysis provided untargeted analysis with detection limits of 0.01 nM to 10 nM. Each 131 sample was run twice (positive ion and negative ion analysis) and data was combined. Di-myristoyl 132 phosphatidylcholine served as an internal standard. Peak finding and quantification for global 133 lipidomics and targeted lipid mediators was performed with Lipid Mass Spectrum Analysis

It is made available under a CC-BY-NC-ND 4.0 International license .

4 of 14

134 (LIMSA) version 1.0 software [30] and MAVEN software [31]. Large blood volumes from this

135 patients population was challenging to obtain, therefore plasma volumes were small (~0.050-0.075 136

- ml total) and higher abundance lipids (~10-1-101) were targeted [32].
- 137 Analysis

138 Percent data were transformed before being analyzed with a beta regression from the R [33] 139 package betareg [34]. Total normalized ion values were log-transformed and analyzed using 140 generalized linear regression models (glm) in R [35]. All regression models were adjusted for age 141 and sex. Contrasts between treatment groups (sick vs. sedation) were conducted using R package 142 emmeans [36]. P-values from the regression models have been corrected for multiple testing via the 143 FDR method. Additional statistical tests that were performed include Welch's t-tets, independent 144 t-tests, and Wilcoxon Rank Sum tests. The p-values from these tests were not multiple testing 145 corrected. Lipid analysis was done on all major lipid classes (as stated above). In this paper we 146 focused on phospholips, given they are heavily influenced by exogenous dietary sources.

147 3. Results

148 Study population

149 Basic characteristics revealed a majority of male (60.6%) Caucasian (57.1%) patients (Table 1). 150 Ages ranged from neonates to adolescents (0.14 - 202 months) with median values of 94.25 months 151 for control patients (range 28.0-122.5), 114.50 months for MODS (range 0.14-202) and 3.5 months for 152 ECMO patients (range 0.5-202), age ranges for both patient groups were similar. Total hospital 153 length of stay (HLOS) ranged between 5-377 days, and total PICU LOS ranged from 3-79 days; 154 ECMO patients spent almost two times as long in the PICU. The majority of patients had a diagnosis 155 of bronchiolitis/pneumonia (7/24; 29%), or sepsis (7/24; 29%). There were two mortalities at 1 years' 156 time, both were patients requiring ECMO. All MODS patients at baseline were mechanically 157 ventilated, had their lungs and heart compromised, and were administered inotropes to support 158 cardiovasular function. More than half of the participants exhibited renal dysfunction (n=15; 54%), 159 including 7 MODS and all 8 ECMO patients (odds ratio: 6.01, p-value=0.01). Other organs affected 160 included liver (n=8; 28.6%; 4 MODS; 4 ECMO) and brain (n=6; 21.4%; 4 MODS; 2 ECMO) in 161 approximately one-quarter. Severity of illness scores Pediatric Logistic Organ Dysfunction-2 score 162 (PELOD) were not significantly different between MODS and ECMO groups across time-points 163 (Global F-stat, p=0.66). This suggests that common metrics of severity do not reflect need for ECMO 164 further suggesting need for additional clinical stratifiers, such as assessing nutrition or lipidomics.

165 Table 1. Patient characteristics of MODS/ECMO Study 2016-2018 (N=28)

Clinical variables	Range	n	% of total	median	IQR	Wilcoxon (all MODS vs sedation)	p-value (all MODS vs sedation)	logistic regression (ECMO vs MODS)	p-value (ECMO vs MODS)
Demographics									
Age (months)		28				45.00	0.87		
Controls	28.0-122 .5	4	14.3	94.25	31.50 ^β				
MODS	0.14-202	16	57.1	114.50	131.00€				
ECMO	0.5-202	8	28.6	3.50	84.00^{\pm}				
Sex (Female)									
Controls		2	7.0						
MODS		7	25.0						

It is made available under a CC-BY-NC-ND 4.0 International license .

- 5	of	1	1
	UI.		+

ECMO		2	7.0						
Ethnicity									
Caucasian/European		16	57.1						
Hispanic		7	25.0						
African American		4	14.3						
Asian/Indian/Pacific		1	3.6						
Diagnosis		24							
Bronchiolitis/		7	20.2						
Pneumoniaª		/	29.2						
Sepsis ^b		7	29.2						
Acute kidney injury		2	8.3						
Cardiac		4	16.7						
Other ^d		4	16.7						
Organs Affected		24							
Lung		24	100.0					0.17	0.68
Liver		8	33.3					2.33	0.13
MODS (n=16)		4	25.0						
ECMO (n=8)		4	50.0						
Kidney		15	62.5					6.01	0.01
MODS (n=16)		8	50.0						
ECMO (n=8)		7	100.0						
Brain		6	25.0					0.41	0.52
MODS (n=16)		5	31.3						
ECMO (n=8)		1	12.5						
PELOD ^e		24		20.0	10.25				0.05
MODS		16		12.5	10.25				
ECMO		8		21.5	11.25				
Outcomes									
HLOS (days)						80.00	0.20		
MODS	5.0-82	16	0.57	20.00	27.00				
ECMO	7.0-377	8	0.29	35.00	11.50				
PICU LOS (days)						77.50	0.27		
MODS	3.0-79	16	0.57	16.00	12.00				
ECMO	7.0-377	8	0.29	31.00	13.00				
Mortality			0.00						
MODS		0	0.00						
ECMO		2	0.07						

166 ECMO: Extracorporeal membrane oxygenation; IQR: inter-quartile range; LOS: length of stay; MODS: 167 Multiorgan Dysfunction Syndrome; PICU: pediatric intensive care unit. For controls (ages: 89.0, 122.5, 99.5, 168 28.0); ^eMODS (0%-0.14; 25%; 13.00; 50%-114.50; 75%-144.00; 100%-202.00); ^eECMO (0%-0.5; 25%-2.0; 50%-3.5; 169 75%-86.0; 100%-202.0). ^aBronchiolitis/Pneumonia: Respiratory syncytial virus (n=2); Rhino/enterovirus, 170 coronavirus (n=1); Klebsiella pneumonia, Staph aureus (n=1); Pseudomonas entomophila (n=1); Metapneumovirus 171 (n=1); Rhinoenterovirus (n=1), bSepsis: Group A Beta Hemolytic Streptococci (n=1); Streptococcus pyogenes (n=2); 172 Coronavirus 229E (n=1); Methicillin-resistant Staphylococcus aureus & Rhino/enterovirus (n=1); 173 Rhino/enterovirus (n=1). Includes acute myocarditis (n=3), dilated cardiomyopathy (n=1). Tracheitis (n=1), 174 Carbon monoxide poisoning (n=1), Hemophagocytic lymphohistiocytosis (n=1), Febrile infection-related 175 epilepsy (n=1). Comprehensive PELOD score; p=value, based on Mann-Whitney rank sum test.

176

177 Baseline Lipid Profiles of Critically ill Children Compared to Controls

178 In order to determine the source of differences in lipid classes at baseline, when most patients 179 (67%) were NPO, we examined absolute normalized abundance (per milliliter of plasma, Figure 2).

180 Lipids in MODS patients (ECMO & MODS combined) differed significantly at baseline from

It is made available under a CC-BY-NC-ND 4.0 International license .

6 of 14

181 sedation control samples after correcting for multiple testing based on generalized linear models 182 adjusted for age and sex for three classes of phospholipids: lysophosphatidylserine (lysoPS) (P -183 value = 0.004), total phosphatidylserine (PS) (P - value = 0.015), and total ether-linked 184 phosphatidylethanolamine (PE) (P-value = 0.03) (Figure 2A). Point estimates and confidence 185 intervals of the differences are presented in Figure 2B. The heatmap revealed relative baseline 186 levels for all lipid classes analysed including NEFAs, glycerolipids and TGs (Figure 2C).

- 187
 - Figure 2: Total Baseline Lipids Based on Absolute Normalized Ion Abundances per ml of Plasma



188

189 A- Bar chart of p-values from regression output; red line indicates 0.05. Any p-value that crosses 0.05 is not 190 statistically significant. B- Points in B represent the mean log(fold-change) in odds between sick and sedation 191 groups. The error bars in B, represent the upper and lower bounds of the false-coverage for the estimate. 95% 192 false coverage intervals of the mean log (fold-change) in odds; red line indicates 0. Any confidence interval 193 that crosses 0 is not statistically significant. C- Scaled values of total lipids based on absolute normalized ion 194 abundances per ml of plasma.

195

196 NEFA levels were further explored and found to be significantly associated with sex. 197 However, after adjusting for sex, none of the experimental groups were significantly associated with 198 NEFA levels at any time point.

199 To serve as an additional internal control, total plasma serine (O-acetyl-L-serine) levels were 200 compared between the three groups, from a metabolite data-set on the same patient cohort (to be 201 presented in a separate report). Mean values were not significantly different (sedation vs MODS; p = 202 0.8281; sedation vs. ECMO; p = 0.3348) based on independent t-test. This may imply that in spite of 203 plasma serine levels, the PS and lysoPS values differ for all MODS patients due to other metabolic 204 drivers.

205 Mode of Feeding and Nutritional Intake

It is made available under a CC-BY-NC-ND 4.0 International license .

7 of 14

206 With detailed notes of nutrition for control and MODS patients, the data can be used to 207 investigate feeding and nutritional intake to elucidate biases in the cohort and to qualitatively 208 control for intake into the lipidomic analyses below. Mode of feeding and percent caloric and protein 209 intake were reviewed for each patient (Table 2). Sedation controls were NPO (nil per os, nothing by 210 mouth) for eight hours prior to procedure. At baseline, 16/24 (67%) of all combined MODS (MODS + 211 MODS who required ECMO) patients were NPO, which decreased (to 7%) by day 8. Baseline caloric 212 intake was less than 33% of recommended intake for most patients, which gradually improved over 213 time. A similar profile was reflected in the percent total protein. ECMO patients by eight days were 214 achieving higher percent calories and protein than their MODS counterparts (over 34% goal 215 reached): ECMO (n=5; 83%) vs. MODS (n=4; 50%) and ECMO (n=6; 100%) vs. MODS (n=4; 50%), 216 respectively. There was no evidence of a statistical difference in the percentages of protein or total 217 calories when tested with with Fisher's exact test (p = 0.085; p = 0.30). All patients were experiencing 218 a deficit nutritionally, however ECMO patients were reaching superior nutritional intake, which 219 may be due to their being more hemodynamically stable because of the circulatory support, better 220 facilitating their caloric need. Of further importance is how this exogenous nutritional intake 221 influences blood plasma lipid profiles for patients over time. Based on this result, we might 222 anticipate that ECMO patients fare better than MODS in terms of overall lipid profiles.

223

224

	Prior to admit	Baseline (%)	72 hours (%)	8 days (%)
Mode of feeds				
All	(n=24)	(n=24)	(n=22)	(n=14)
РО	13 (54.2)	0 (0.0)	0 (0.0)	1 (7.1)
TF	8 (33.3)	6 (25.0)	10 (45.5)	9 (64.3)
TF + TPN/Lipids	0 (0.0)	0 (0.0)	2 (9.1)	2 ^b (14.3)
TPN/Lipids	0 (0.0)	2ª (8.3)	5° (22.7)	1 (7.1)
NPO	0 (0.0)	16 (66.7)	4 (18.2)	1 ^d (7.1)
N/A	3 (12.5)	0 (0.0)	1 (4.5)	0 (0.0)
MODS	(n=16)	(n=16)	(n=15)	(n=8)
PO	9 (56.3)	0 (0.0)	0 (0.0)	1 (12.5)
TF	5 (31.3)	4 (25.0)	9 (60.0)	7 (87.5)
TF + TPN/Lipids	0 (0.0)	0 (0.0)	1 (6.7)	0 (0.0)
TPN/Lipids	0 (0.0)	2ª (12.5)	2 (13.3)	0 (0.0)
NPO	0 (0.0)	10 (62.5)	2 (13.3)	0 (0.0)
N/A	2 (12.5)	0 (0.0)	1 (6.7)	0 (0.0)
ЕСМО	(n=8)	(n=8)	(n=7)	(n=6)
PO	4 (50.0)	0 (0.0)	0 (0.0)	0 (0.0)
TF	3 (37.5)	2 (25.0)	1 (14.3)	2 (33.3)
TF + TPN/Lipids	0 (0.0)	0 (0.0)	1 (14.3)	2 ^b (33.3)
TPN/Lipids	0 (0.0)	0 (0.0)	3º (42.9)	1 (16.7)
NPO	0 (0.0)	6 (75.0)	2 (28.6)	1 (16.7)
N/A	1 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)
<u>% Calories Met</u>				
All	(n=24)	(n=24)	(n=22)	(n=14)
<u><</u> 33	N/A	19 (79.2)	9 (40.9)	5 (35.7)
34-66	N/A	1 (4.2)	8 (36.4)	6 (42.8)
<u>≥</u> 67	N/A	2 (8.3)	4 (18.2)	3 (21.4)
N/A	N/A	2 (8.3)	1 (4.5)	0 (0.0)

Table 2. Patient Nutrition for MODS/ECMO Study 2016-2018 (N=24)

It is made available under a CC-BY-NC-ND 4.0 International license .

8 of 14

MODS	(n=16)	(n=16)	(n=15)	(n=8)
<u><</u> 33	N/A	12 (75.0)	6 (40.0)	4 (50.0)
34-66	N/A	1 (6.3)	4 (26.7)	3 (37.5)
<u>></u> 67	N/A	1 (6.3)	4 (26.7)	1 (12.5)
N/A	N/A	2 (12.5)	1 (6.7)	0 (0.0)
ECMO	(n=8)	(n=8)	(n=7)	(n=6)
<u>≤</u> 33	N/A	7 (87.5)	3 (42.9)	1 (16.7)
34-66	N/A	0 (0.0)	4 (57.1)	3 (50.0)
<u>></u> 67	N/A	1 (12.5)	0 (0.0)	2 (33.3)
N/A	N/A	0 (0.0)	0 (0.0)	0 (0.0)
<u>% Protein Met</u>	((((1 1)
All	(n=24)	(n=24)	(n=22)	(n=14)
<u><</u> 33	N/A	19 (79.2)	9 (40.9)	4(28.6)
34-66	N/A	2 (8.3)	8 (36.4)	4 (28.6)
>6'/	N/A	1 (4.2)	4 (18.2)	6 (42.9)
N/A	N/A	2 (8.3)	1 (4.5)	0 (0.0)
MODS	(n=16)	(n=16)	(n=15)	(n=8)
<33	N/A	12 (75.0)	6 (40.0)	4 (50.0)
_ 34-66	N/A	1 (6.3)	5 (33.3)	2 (25.0)
>67	N/A	1 (6.3)	3 (20.0)	2 (25.0)
N/A	N/A	2 (12.5)	1 (6.7)	0 (0.0)
		``	~ /	· · ·
ECMO	(n=8)	(n=8)	(n=7)	(n=6)
<33	N/A	7 (87.5)	3 (42.9)	0 (0.0)
34-66	N/A	1 (12.5)	3 (42.9)	2 (33.3)
<67	N/A	0 (0.0)	1 (14.3)	4 (66.7)
N/A	N/A	0 (0.0)	0 (0.0)	0 (0.0)
D C	(24)	((22)	(1.4)
Kesp. Supp.	(n=24)	(n=24)	(n=22)	(n=14)
MV	U (U.U)	22 (91.7)	21 (95.5)	11 (78.6)
NC	2 (8.3)	1 (4.2)	U (U.U)	1 (7.1)
KA	22 (91.7)	1 (4.2)	1 (4.5)	2 (14.3)
N/A	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

ECMO: extracorporeal membrane oxygenation; MODS: multi-organ dysfunction syndrome; MV: mechanical ventilation; NC: nasal cannula; NPO: *nil per os*-also used here to mean no nutrition support administered; PO: *per os*/oral feeds; RA: room air; Resp. Supp: Respiratory Support; TF: tube feeding; TPN: total parenteral nutrition. ^aOne patient lipids only; ^bOne patient TF + TPN, no lipids; ^cOne patient no lipids; ^dPatient NPO however qualified in the <33% calories/protein met. N/A: no nutritional assessment.

230

231 Phospholipids of Critically ill Children Over Three Time Points

232

Surprisingly, for MODS patients that needed ECMO, their distribution of phospholipids appear more similar to patients coming to the hospital for same day sedation instead of looking like that of other MODS patients (Figure 3). Phospholipid levels appeared to increase with percent nutritional (caloric and protein) needs being met (Table 2). A total of five patients (n=2 MODS; n=3 ECMO) over seven time points received IV lipids as a portion of their nutritional regimen. Two patients received lipids at more than one time-point, both with slight increases in their plasma phospholipid levels.

It is made available under a CC-BY-NC-ND 4.0 International license .

9 of 14

239These differences may not be based on nutrition intake alone, given most patients were NPO240(67%) at baseline, and receiving less than 33% of needed intake (79%), suggesting other metabolite

- 241 drivers at play.
- 242
- 243

Figure 3: Time course for lipids over 8 days.



245

In summary, we see down-regulated phospholipid levels including sub-classes (lyso PS, PS, PE)
at baseline for patients with MODS, with increases by day 8, except for those with MODS that
needed ECMO (Figure 2, 3). We observe increases in phospholipids that correspond to nutritional
intake patients received.

250 4. Discussion

251 Patients with MODS present with dyslipidemia at first detection of organ pathology based on 252 our lipidomic profiles presented in this report. Patients with MODS are compromised at the time of 253 baseline, undergoing membrane disruption/remodeling, catabolic state, canabalism, and lipid 254 dysregulation [37], resulting in decreased phospholipids as has been previously reported for 255 pneumonia [38] and septic patients [39]. In contrast to the MODS patients, ECMO patients have 256 phospholipid profiles that are observedly different at baseline and throughout the eight-day course. 257 Some reports state that phospholipids from endogenous sources such as the hepatobiliary system 258 [40] are involved with signaling of the innate immune response [41]. In the event of multi-organ 259 dysfunction, with liver involvement (as we see in half of our ECMO patients), perhaps this is not 260 entirely surprising. We suspect that this observed difference in ECMO patients may be tied to severe 261 cardiac dysfunction with an inability to compensate metabolically. Generally, risk factors for this 262 sub-population may include pre-existing conditions such un-diagnosed conditions, metabolic 263 syndrome or other organ pathologies, which has been seen in current COVID-19 cases [42].

Recent studies in COVID 19 infections have found patients that suffer from multi-organ involvement are more prone to mortality [43]. A subclass of PS, ether-linked phosphatidylester were

It is made available under a CC-BY-NC-ND 4.0 International license .

found to be among the lowest-abundance lipids in COVID patients. An untargeted lipidomics
approach was adopted for COVID-19 patients which revealed lower levels of certain classes of lipids
which persisted even with a regular diet and discharge home [44]. This finding is indicative of
ongoing metabolic disruption, post-ICU admission.

Specifically, a sub-class of lyso lipids known as -Lyso phosphatidylserine (LysoPS) has immune function [45,46] through enhanced clearance of neutrophils [47]. Synthesized by neutrophils [48-50], LysoPS enhances efferocytosis ("to carry to the grave" [51]) of neutrophils by macrophages [52] during acute inflammation [53,54]. Neutrophil levels were lower and more like controls in patients that needed ECMO [55] and other studies have shown that neutrophil levels drop in the sickest patients as bone marrow activity becomes suppressed. This may lead to the lower levels of LysoPS.

277 Over the past decades, the externalization of PS has been linked with efferocytosis, and 278 characterized as the ultimate "eat-me" signal, is an evolutionarily conserved immunosuppressive 279 signal, which prevents local and systemic immune activation [56]. This externalization of PS has 280 been shown to be exploited by viruses, microorganisms, and parasites to promote infection [56]. This 281 could link PS levels seen in our cohort to infection in our cohort as many of our patients presented 282 with bronchiolitis, pneumonia and sepsis, two of which had Coronavirus (OC43 and HKU1). Many 283 of the patients in this study had viral illness as a trigger or in addition to MODS, as is typical in the 284 PICUs across the country.

Untargeted lipidomic research done previously in adult patients (n=30) with acute respiratory distress syndrome (ARDS) using a shot-gun lipidomics approach revealed 90 significantly different lipids that distinguished survivors from non-survivors[13]. Similarly, in children it has been shown that profiling metabolites for septic shock and systemic inflammatory response syndrome (SIRS) can yield markers of mortality [23].

290 This study shows that phospholipids in ECMO patients observedly grouped closer to the 291 sedation patients. In all these patients, the lipidome is reflective of an amalgam of multiple pathways 292 that include the inflammatory cascade, immune dysfunction, severity of illness and nutritional 293 status, all of which could combine to effect clinical course. Age was accounted for in the models 294 (given ECMO patients were younger than the MODS), as was suspected that immature immunity or 295 active suppression of the immune system and a confounder [57]. ECMO patients seem to have their 296 ability to modify their lipidome impeded as the concentrations of major lipid classes are closer to 297 sedation controls.

298 5. Conclusions

In this prospective observational study we studied several lipid classes at multiple time-points and identified that phospholipids showed differences between all MODS and sedation, and MODS vs. MODS needing ECMO using a shotgun lipidomics approach. Future work may include a targeted lipidomic approach on phospholipids. Patient lipid profiles can be partially modified with nutritional intervention.

304 Supplementary Materials: N/A.

305 Author Contributions: SR and ML conceived of the original study design, screened, recruited and collected all 306 samples. ML and EW were the statistical and bioinformatics support. KF reviewed all of the nutrition 307 information for individual patients. Peak findings, annotation, and quantification for lipidomics were 308 performed by TL. SR, DS, ML, EW, BB, JP, KF and TL all contributed to the writing and editing of the 309 manuscript.

Funding: This research was funded by the Spectrum Health Office of Research, grant #R51100431217, and HDVCH Foundation, grant #R51100881018.

- **Acknowledgments**: The authors would like to thank the PICU staff at Helen DeVos Children's Hospital for their support in the completion of this study and various contributions, and Brittany Essenmacher, Dr. Jocelyn
- 314 Grunwell and Dr. Eric Kort for their critical review of the final manuscript.
- 315 **Conflicts of Interest**: The authors declare no conflict of interest.

316

It is made available under a CC-BY-NC-ND 4.0 International license .

11 of 14

317 References:

318	1.	Typpo, K.V.; Petersen, N.J.; Hallman, D.M.; Markovitz, B.P.; Mariscalco, M.M. Day 1 multiple organ
319		dysfunction syndrome is associated with poor functional outcome and mortality in the pediatric
320		intensive care unit. Pediatr Crit Care Med 2009, 10, 562-570, doi:10.1097/PCC.0b013e3181a64be1.
321	2.	Typpo, K.; Watson, R.S.; Bennett, T.D.; Farris, R.W.D.; Spaeder, M.C.; Petersen, N.J.; Pediatric Existing
322		Data Analysis, I.; Pediatric Acute Lung, I.; Sepsis Investigators, N. Outcomes of Day 1 Multiple Organ
323		Dysfunction Syndrome in the PICU. Pediatr Crit Care Med 2019, 20, 914-922,
324		doi:10.1097/PCC.00000000002044.
325	3.	Barbaro, R.P.; Paden, M.L.; Guner, Y.S.; Raman, L.; Ryerson, L.M.; Alexander, P.; Nasr, V.G.; Bembea,
326		M.M.; Rycus, P.T.; Thiagarajan, R.R. Pediatric Extracorporeal Life Support Organization Registry
327		International Report 2016. ASAIO journal (American Society for Artificial Internal Organs : 1992) 2017, 63,
328		456-463, doi:10.1097/mat.0000000000000003.
329	4.	Yuki, K.; Fujiogi, M.; Koutsogiannaki, S. COVID-19 pathophysiology: A review. Clinical immunology
330		(Orlando, Fla.) 2020 , 215, 108427, doi:10.1016/j.clim.2020.108427.
331	5.	Cascella, M.; Rajnik, M.; Cuomo, A.; Dulebohn, S.C.; Di Napoli, R. Features, Evaluation and
332		Treatment Coronavirus (COVID-19). In StatPearls, StatPearls Publishing Copyright © 2020, StatPearls
333		Publishing LLC.: Treasure Island (FL), 2020.
334	6.	Coss-Bu, J.A.; Klish, W.J.; Walding, D.; Stein, F.; Smith, E.O.; Jefferson, L.S. Energy metabolism,
335		nitrogen balance, and substrate utilization in critically ill children. Am J Clin Nutr 2001, 74, 664-669.
336	7.	Kraft, R.; Herndon, D.N.; Finnerty, C.C.; Hiyama, Y.; Jeschke, M.G. Association of postburn fatty acids
337		and triglycerides with clinical outcome in severely burned children. The Journal of clinical endocrinology
338		and metabolism 2013 , 98, 314-321, doi:10.1210/jc.2012-2599.
339	8.	Jeschke, M.G.; Finnerty, C.C.; Herndon, D.N.; Song, J.; Boehning, D.; Tompkins, R.G.; Baker, H.V.;
340		Gauglitz, G.G. Severe injury is associated with insulin resistance, endoplasmic reticulum stress
341		response, and unfolded protein response. Ann Surg 2012, 255, 370-378,
342		doi:10.1097/SLA.0b013e31823e76e7.
343	9.	Joosten, K.F.; Kerklaan, D.; Verbruggen, S.C. Nutritional support and the role of the stress response in
344		critically ill children. Curr Opin Clin Nutr Metab Care 2016, 19, 226-233,
345		doi:10.1097/MCO.00000000000268.
346	10.	Hoffer, L.J.; Bistrian, B.R. Why critically ill patients are protein deprived. JPEN J Parenter Enteral Nutr
347		2013 , 37, 300-309, doi:10.1177/0148607113478192.
348	11.	Crouser, E.D. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome.
349		Mitochondrion 2004 , 4, 729-741, doi:10.1016/j.mito.2004.07.023.
350	12.	Modre-Osprian, R.; Osprian, I.; Tilg, B.; Schreier, G.; Weinberger, K.M.; Graber, A. Dynamic
351		simulations on the mitochondrial fatty acid beta-oxidation network. BMC Syst Biol 2009, 3, 2,
352		doi:10.1186/1752-0509-3-2.
353	13.	Maile, M.D.; Standiford, T.J.; Engoren, M.C.; Stringer, K.A.; Jewell, E.S.; Rajendiran, T.M.; Soni, T.;
354		Burant, C.F. Associations of the plasma lipidome with mortality in the acute respiratory distress
355		syndrome: a longitudinal cohort study. Respir Res 2018, 19, 60-60, doi:10.1186/s12931-018-0758-3.
356	14.	Briassoulis, G.; Venkataraman, S.; Thompson, A. Cytokines and metabolic patterns in pediatric
357		patients with critical illness. <i>Clin Dev Immunol</i> 2010, 2010, 354047, doi:10.1155/2010/354047.
358	15.	Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z. The metabolic syndrome. Lancet 2005, 365, 1415-1428,
359		doi:10.1016/S0140-6736(05)66378-7.

It is made available under a CC-BY-NC-ND 4.0 International license .

12 of 14

360	16.	Savage, D.B.; Petersen, K.F.; Shulman, G.I. Mechanisms of insulin resistance in humans and possible
361		links with inflammation. Hypertension 2005, 45, 828-833, doi:10.1161/01.HYP.0000163475.04421.e4.
362	17.	Steinberg, D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of
363		the cholesterol controversy: part I. J Lipid Res 2004, 45, 1583-1593, doi:10.1194/jlr.R400003-JLR200.
364	18.	Steinberg, D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of
365		the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary
366		disease in humans. J Lipid Res 2005, 46, 179-190, doi:10.1194/jlr.R400012-JLR200.
367	19.	Wellen, K.E.; Hotamisligil, G.S. Inflammation, stress, and diabetes. J Clin Invest 2005, 115, 1111-1119,
368		doi:10.1172/JCI25102.
369	20.	Ott, J.; Hiesgen, C.; Mayer, K. Lipids in critical care medicine. Prostaglandins, leukotrienes, and essential
370		fatty acids 2011 , 85, 267-273, doi:10.1016/j.plefa.2011.04.011.
371	21.	Mogensen, K.M.; Lasky-Su, J.; Rogers, A.J.; Baron, R.M.; Fredenburgh, L.E.; Rawn, J.; Robinson, M.K.;
372		Massarro, A.; Choi, A.M.; Christopher, K.B. Metabolites Associated With Malnutrition in the Intensive
373		Care Unit Are Also Associated With 28-Day Mortality. JPEN J Parenter Enteral Nutr 2017, 41, 188-197,
374		doi:10.1177/0148607116656164.
375	22.	Postle, A.D. Phospholipid lipidomics in health and disease. Eur J Lipid Sci Technol 2009, 111, 2-13,
376		doi:10.1002/ejlt.200800158.
377	23.	Sales, S.; Graessler, J.; Ciucci, S.; Al-Atrib, R.; Vihervaara, T.; Schuhmann, K.; Kauhanen, D.; Sysi-Aho,
378		M.; Bornstein, S.R.; Bickle, M., et al. Gender, Contraceptives and Individual Metabolic Predisposition
379		Shape a Healthy Plasma Lipidome. Scientific reports 2016, 6, 27710, doi:10.1038/srep27710.
380	24.	Prokop, J.W.; Shankar, R.; Gupta, R.; Leimanis, M.L.; Nedveck, D.; Uhl, K.; Chen, B.; Hartog, N.L.;
381		Van Veen, J.; Sisco, J.S., et al. Virus-induced genetics revealed by multidimensional precision
382		medicine transcriptional workflow applicable to COVID-19. Physiological genomics 2020, 52, 255-268,
383		doi:10.1152/physiolgenomics.00045.2020.
384	25.	Proulx, F.; Fayon, M.; Farrell, C.A.; Lacroix, J.; Gauthier, M. Epidemiology of sepsis and multiple
385		organ dysfunction syndrome in children. Chest 1996, 109, 1033-1037, doi:10.1378/chest.109.4.1033.
386	26.	Schofield, W.N. Predicting basal metabolic rate, new standards and review of previous work. Human
387		nutrition. Clinical nutrition 1985 , 39 Suppl 1, 5-41.
388	27.	Medicine, I.o. Dietary Reference Intakes: The Essential Guide to Nutrient Requirements; The National
389		Academies Press: Washington, DC, 2006; doi:10.17226/11537pp. 1344.
390	28.	Harris, P.A.; Taylor, R.; Thiekle, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic capture
391		(REDCap) - A metadata-driven methodology and workflow process for providing translational
392		research informatics supports. Journal of Biomedical Information 2009, 42, 377-381.
393	29.	Cai, X.; Li, R. Concurrent profiling of polar metabolites and lipids in human plasma using
394		HILIC-FTMS. Scientific reports 2016, 6, 36490, doi:10.1038/srep36490.
395	30.	Haimi, P.; Uphoff, A.; Hermansson, M.; Somerharju, P. Software tools for analysis of mass
396		spectrometric lipidome data. Anal Chem 2006, 78, 8324-8331, doi:10.1021/ac061390w.
397	31.	Clasquin, M.F.; Melamud, E.; Rabinowitz, J.D. LC-MS data processing with MAVEN: a metabolomic
398		analysis and visualization engine. Curr Protoc Bioinformatics 2012, Chapter 14, Unit14 11,
399		doi:10.1002/0471250953.bi1411s37.
400	32.	Vuckovic, D. Improving metabolome coverage and data quality: advancing metabolomics and
401		lipidomics for biomarker discovery. Chemical communications (Cambridge, England) 2018, 54, 6728-6749,
402		doi:10.1039/c8cc02592d.

It is made available under a CC-BY-NC-ND 4.0 International license .

13 of 14

403	33.	Team, R.C. R: A language and environment for statistical computing., Vienna, Austria, 2019.
404	34.	Cribari-Neto, F.; Zeileis, A. Beta Regression in R. Journal of Statistical Software 2010, 34, 1-24.
405	35.	Bates, D.; Maehler, M.; Bolker, B.; Walker, S. Fitting Linear Mixed-Effects Models Using Ime4. Journal
406		of Statistical Software 2015 , 67, 1-48, doi:10.18637/jss.v067.i01.
407	36.	Lenth, R. Emmeans: Estimated Marginal Means, aka Least-Squares Means. R package version 1.4 2019.
408	37.	Van Dreden, P.; Woodhams, B.; Rousseau, A.; Dreyfus, J.F.; Vasse, M. Contribution of procoagulant
409		phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in
410		intensive care patients with septic and non-septic organ failure. Clinical chemistry and laboratory
411		<i>medicine</i> 2013 , <i>51</i> , 387-396, doi:10.1515/cclm-2012-0262.
412	38.	Arshad, H.; Alfonso, J.C.L.; Franke, R.; Michaelis, K.; Araujo, L.; Habib, A.; Zboromyrska, Y.; Lücke,
413		E.; Strungaru, E.; Akmatov, M.K., et al. Decreased plasma phospholipid concentrations and increased
414		acid sphingomyelinase activity are accurate biomarkers for community-acquired pneumonia. Journal
415		of translational medicine 2019 , 17, 365, doi:10.1186/s12967-019-2112-z.
416	39.	Caspar-Bauguil S.; Genestal M. Plasma Phospholipid Fatty Acid Profiles in Septic Shock. In Diet and
417		Nutrition in Critical Care, R., R., V.R., P., V.B., P., Eds. Springer: New York, NY, 2015; DOI
418		10.1007/978-1-4614-7836-2_137p. 219.
419	40.	Monte, M.J.; Cava, F.; Esteller, A.; Jimenez, R. Inhibition of biliary cholesterol and phospholipid
420		secretion during cyclobutyrol-induced hydrocholeresis. The Biochemical journal 1989, 263, 513-518,
421		doi:10.1042/bj2630513.
422	41.	O'Donnell, V.B.; Rossjohn, J.; Wakelam, M.J. Phospholipid signaling in innate immune cells. The
423		Journal of clinical investigation 2018, 128, 2670-2679, doi:10.1172/JCI97944.
424	42.	Dietz, W.; Santos-Burgoa, C. Obesity and its Implications for COVID-19 Mortality. Obesity (Silver
425		Spring, Md.) 2020 , 28, 1005, doi:10.1002/oby.22818.
426	43.	Du, Y.; Tu, L.; Zhu, P.; Mu, M.; Wang, R.; Yang, P.; Wang, X.; Hu, C.; Ping, R.; Hu, P., et al. Clinical
427		Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J
428		Respir Crit Care Med 2020, 201, 1372-1379, doi:10.1164/rccm.202003-0543OC.
429	44.	Wu, D.; Shu, T.; Yang, X.; Song, JX.; Zhang, M.; Yao, C.; Liu, W.; Huang, M.; Yu, Y.; Yang, Q., et al.
430		Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19. National Science Review
431		2020 , 10.1093/nsr/nwaa086, doi:10.1093/nsr/nwaa086.
432	45.	Sugo, T.; Tachimoto, H.; Chikatsu, T.; Murakami, Y.; Kikukawa, Y.; Sato, S.; Kikuchi, K.; Nagi, T.;
433		Harada, M.; Ogi, K., et al. Identification of a lysophosphatidylserine receptor on mast cells. Biochem
434		Biophys Res Commun 2006 , 341, 1078-1087, doi:10.1016/j.bbrc.2006.01.069.
435	46.	Bruni A.; Mietto L.; Bellini F.; Ponzin D.; Caselli E.; Toffano G. Regulation of immune cells by serine
436		phospholipids. In Molecular Basis of Neurological Disorders and Their Treatment, J.W., G., O., A., E., F., S.,
437		P., Eds. Springer: Dordrecht, 1991.
438	47.	Frasch, S.C.; Zemski-Berry, K.; Murphy, R.C.; Borregaard, N.; Henson, P.M.; Bratton, D.L.
439		Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant
440		signaling through G2A. Journal of immunology (Baltimore, Md. : 1950) 2007 , 178, 6540-6548,
441		doi:10.4049/jimmunol.178.10.6540.
442	48.	Frasch, S.C.; Berry, K.Z.; Fernandez-Boyanapalli, R.; Jin, H.S.; Leslie, C.; Henson, P.M.; Murphy, R.C.;
443		Bratton, D.L. NADPH oxidase-dependent generation of lysophosphatidylserine enhances clearance of
444		activated and dying neutrophils via G2A. The Journal of biological chemistry 2008, 283, 33736-33749,
445		doi:10.1074/jbc.M807047200.

It is made available under a CC-BY-NC-ND 4.0 International license .

14 of 14

446	49.	Frasch, S.C.; Fernandez-Boyanapalli, R.F.; Berry, K.Z.; Leslie, C.C.; Bonventre, J.V.; Murphy, R.C.;
447		Henson, P.M.; Bratton, D.L. Signaling via macrophage G2A enhances efferocytosis of dying
448		neutrophils by augmentation of Rac activity. The Journal of biological chemistry 2011 , 286, 12108-12122,
449		doi:10.1074/jbc.M110.181800.
450	50.	Hosono, H.; Aoki, J.; Nagai, Y.; Bandoh, K.; Ishida, M.; Taguchi, R.; Arai, H.; Inoue, K.
451		Phosphatidylserine-specific phospholipase A1 stimulates histamine release from rat peritoneal mast
452		cells through production of 2-acyl-1-lysophosphatidylserine. <i>The Journal of biological chemistry</i> 2001 ,
453		276, 29664-29670, doi:10.1074/jbc.M104597200.
454	51.	deCathelineau, A.M.; Henson, P.M. The final step in programmed cell death: phagocytes carry
455		apoptotic cells to the grave. <i>Essays Biochem</i> 2003 , <i>39</i> , 105-117, doi:10.1042/bse0390105.
456	52.	Bratton, D.L.; Henson, P.M. Neutrophil clearance: when the party is over, clean-up begins. Trends in
457		immunology 2011 , 32, 350-357, doi:10.1016/j.it.2011.04.009.
458	53.	Frasch, S.C.; Fernandez-Boyanapalli, R.F.; Berry, K.A.; Murphy, R.C.; Leslie, C.C.; Nick, J.A.; Henson,
459		P.M.; Bratton, D.L. Neutrophils regulate tissue Neutrophilia in inflammation via the oxidant-modified
460		lipid lysophosphatidylserine. The Journal of biological chemistry 2013, 288, 4583-4593,
461		doi:10.1074/jbc.M112.438507.
462	54.	Frazier, W.J.; Hall, M.W. Immunoparalysis and adverse outcomes from critical illness. Pediatr Clin
463		North Am 2008 , 55, 647-668, xi, doi:10.1016/j.pcl.2008.02.009.
464	55.	Shankar, R.; Leimanis, M.L.; Newbury, P.A.; Liu, K.; Xing, J.; Nedveck, D.; Kort, E.J.; Prokop, J.W.;
465		Zhou, G.; Bachmann, A.S., et al. Gene expression signatures identify pediatric patients with multiple
466		organ dysfunction who require advanced life support in the intensive care unit. medRXiv 2020,
467		10.1101/2020.02.15.20022772, doi:10.1101/2020.02.15.20022772.
468	56.	Birge, R.B.; Boeltz, S.; Kumar, S.; Carlson, J.; Wanderley, J.; Calianese, D.; Barcinski, M.; Brekken, R.A.;
469		Huang, X.; Hutchins, J.T., et al. Phosphatidylserine is a global immunosuppressive signal in
470		efferocytosis, infectious disease, and cancer. Cell Death Differ 2016, 23, 962-978,
471		doi:10.1038/cdd.2016.11.
472	57.	Gervassi, A.L.; Horton, H. Is Infant Immunity Actively Suppressed or Immature? Virology (Auckl)
473		2014 , 2014, 1-9, doi:10.4137/VRT.S12248.

474